Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary shares by nine individuals on January 12, 2011, at a price of £12.29 per share through the Company's Share Reward Plan. The transactions involved:
- Mr A P Witty
- Mr J S Heslop
- Mr S M Bicknell
- Mr E J Gray
- Mr D S Redfern
- Ms C Thomas
- Dr P J T Vallance
- Mrs V A Whyte
Each individual acquired 10 shares under the partnership element (personal contribution) and 10 shares under the matching element (Company contribution), except Dr P J T Vallance, whose order of acquisition was listed differently but involved the same quantities.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of director share interests.
Investor Verification Points
- Verify the share price of £12.29 per Ordinary share on January 12, 2011.
- Confirm the total number of shares acquired by each listed director (20 shares per person).
- Review the terms of the Company's Share Reward Plan to understand the matching contribution structure.
- Note that this filing does not contain financial performance data for the period.